Silence Therapeutics plc (SLN)
NASDAQ: SLN · Real-Time Price · USD
6.35
+0.12 (1.93%)
At close: Dec 19, 2025, 4:00 PM EST
6.26
-0.09 (-1.42%)
After-hours: Dec 19, 2025, 7:18 PM EST
Silence Therapeutics Revenue
Silence Therapeutics had revenue of $159.00K in the quarter ending September 30, 2025, a decrease of -89.39%. This brings the company's revenue in the last twelve months to $23.77M, up 11.82% year-over-year. In the year 2024, Silence Therapeutics had annual revenue of $41.20M with 27.54% growth.
Revenue (ttm)
$23.77M
Revenue Growth
+11.82%
P/S Ratio
11.72
Revenue / Employee
$222,672
Employees
116
Market Cap
300.88M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 41.20M | 8.90M | 27.54% |
| Dec 31, 2023 | 32.30M | 10.65M | 49.17% |
| Dec 31, 2022 | 21.66M | 4.87M | 29.01% |
| Dec 31, 2021 | 16.78M | 9.29M | 124.07% |
| Dec 31, 2020 | 7.49M | 7.17M | 2,215.11% |
| Dec 31, 2019 | 323.57K | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | 21.62K | -928.69K | -97.72% |
| Dec 31, 2016 | 950.31K | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | 23.37K | -170.40K | -87.94% |
| Dec 31, 2013 | 193.77K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
SLN News
- 5 days ago - Silence Therapeutics Announces Leadership Changes - Business Wire
- 4 weeks ago - Silence Therapeutics: Divesiran Targets High-Burden PV - Seeking Alpha
- 5 weeks ago - Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference - Business Wire
- 6 weeks ago - Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights - Business Wire
- 2 months ago - Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV) - Business Wire
- 3 months ago - Silence Therapeutics Plc (SLN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 3 months ago - Silence Therapeutics to Participate in September Investor Conferences - Business Wire
- 4 months ago - Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - Business Wire